about
Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?Developing biomarkers in mood disorders research through the use of rapid-acting antidepressantsSecond messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorderTargeted opioid receptor antagonists in the treatment of alcohol use disordersNeurobiology of anxious depression: a reviewGlutamate and its receptors in the pathophysiology and treatment of major depressive disordercAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor.In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia.Do the dissociative side effects of ketamine mediate its antidepressant effects?Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram.Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder.Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.Subtypes of major depression in substance dependence.Pharmacologic treatment of dimensional anxious depression: a reviewAnticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.Riluzole likely lacks antidepressant efficacy in ketamine non-responders.Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.Clinical predictors of ketamine response in treatment-resistant major depression.Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depressionA single infusion of ketamine improves depression scores in patients with anxious bipolar depression.Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar DepressionAssessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.Ketamine for depression: evidence, challenges and promiseNMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophreniaReliability of 7T (1) H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation.A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorderSecond messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder.Defining anxious depression: a review of the literature.NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER.A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar DisorderThe role of adipokines in the rapid antidepressant effects of ketamine.Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.Therapeutic Modulation of Glutamate Receptors in Major Depressive DisorderOverview of glutamatergic neurotransmission in the nervous system.Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder.Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
P50
Q26829556-427F1ED7-F68E-47A7-B5DC-0F18EB40B50DQ26996955-5292514C-4619-4225-B657-7818AAC6F58DQ27002419-5DFB8703-5488-416B-A873-A3E96A6AED7BQ28295125-6480BACF-FC3F-4161-8DFB-4648224E782BQ30440739-D8963B7A-ADBB-4377-A9F2-ABA0514A6592Q30711088-3B96E44E-A237-4638-BD06-45054E008B38Q33554709-4F83F6A9-C104-4AAC-B463-F5AF4F2174D8Q33605318-99C4976F-BB84-46A3-A573-2B2F031968B8Q33787133-C7293E44-CC87-4274-A403-0FCDA4D5037BQ33874459-6A68AFCB-08FF-4260-9C2F-B99D2660888DQ34167805-05B68896-4A58-4EBF-9AE9-FA16CE611264Q34177760-2D610AEA-0FD1-4144-9D0D-5C07F9EB6F1EQ34181837-D8E42FE8-0F93-460B-B2AA-28D91F1AAD55Q34241455-FFAF8FFC-FF6C-4E0A-8238-7AE463551E8FQ34307234-5EBD300F-32D4-4ECB-A03F-EB47C3569978Q34331887-36BB7125-385B-46C3-BBC2-13E19299D8CFQ34472695-B2C57A90-276C-4A59-A464-15B5FEFC13B3Q34475595-35960930-E4A0-41CF-AA3F-8696E4FF9D87Q34989048-4999C1F4-8BC4-4E1E-99E2-CDE102F6E6D6Q35001345-1E25E1E5-5505-4A23-BEB3-8525B37887A9Q35026766-754F0C9A-2B4A-40DE-9869-199F811C5001Q35449610-21CED119-F029-4A78-8AFD-D94F2DEEEA18Q35607157-88E1A585-31D6-40D7-8681-6F2858C19CB6Q35763203-944F7784-6F9A-46C7-9838-C64D5095B64EQ35908061-4EC06C06-2616-4FE9-9E40-ECD60265DDE0Q36118741-966CCFB9-AE82-47E8-A546-0372CE13D0C6Q36339850-F5CF5BD0-6088-454F-9DBB-114BAA32246DQ36352405-CFFECF61-6830-441A-98E1-12F8239D78BBQ36747222-BC0462E8-3CA3-41D8-9506-BFC6DAFA0CF5Q37113536-485CCE92-E8EF-474B-95EA-BA36BB71BEC0Q37172240-669E1036-05CD-4A24-8AC7-B66953019B16Q37343344-2E0BEF03-D964-4CED-A1E2-F35C724509FFQ37405727-C4B77C04-2D64-4453-9856-AE9A9C7CC44BQ37405730-0C82C302-B261-4E45-B2E3-8ED0DBB0515CQ37418553-BB2220B4-FAD5-4825-A06E-E2A11C3D9549Q37424327-C9850033-110E-4333-964C-000024352A7DQ37668014-F2C9ED4F-55D8-4E03-A355-A7EC9CDA772CQ37926162-48C20D46-6A2E-4A25-BD4C-BE3517939E05Q38383728-346CD2CE-D2BA-406C-AA6C-27EED46921E1Q38422554-C3DAB347-7DBB-4C0F-99F0-CB43CE84F4F6
P50
description
researcher
@en
name
Mark J Niciu
@en
Mark J Niciu
@nl
type
label
Mark J Niciu
@en
Mark J Niciu
@nl
prefLabel
Mark J Niciu
@en
Mark J Niciu
@nl
P106
P31
P496
0000-0002-5612-3021